Actively Recruiting
Study on How Gender Affects Safety and Effectiveness of Lenvatinib in Adults With Radioiodine Resistant Differentiated Thyroid Cancer
Led by Regina Elena Cancer Institute · Updated on 2024-12-06
50
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying how gender differences affect the safety and effectiveness of lenvatinib in patients with radioiodine refractory differentiated thyroid cancer DTC. Lenvatinib is an approved oral drug that inhibits certain growth factor receptors and has shown significant activity in treating DTC resistant to radioiodine treatment. This observational study aims to understand how men and women differ in their response and side effects from lenvatinib treatment in a real-world setting. Participants will be patients with refractory iodine DTC who are treated with lenvatinib following good clinical practice guidelines. The study observes patients as they receive lenvatinib, without assigning treatments, to assess differences in dose reduction needs, side effects, tumor response, progression-free survival, and overall survival over a one-year period. During the study, researchers will monitor and collect data on safety, toxicity, adverse events, tumor response according to RECIST criteria, and survival outcomes. These measures will help clarify gender-based differences in treatment effects. Participants will be followed for at least one year to evaluate these outcomes comprehensively.
CONDITIONS
Brief Title
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Research Team
M
Marialuisa Appetecchia, Prof
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
